Literature DB >> 28097622

Selenium rescues orbital fibroblasts from cell death induced by hydrogen peroxide: another molecular basis for the effects of selenium in graves' orbitopathy.

Giovanna Rotondo Dottore1, Riccardo Chiarini1, Maria De Gregorio1, Marenza Leo1, Giamberto Casini2, Luca Cestari2, Stefano Sellari-Franceschini3, Marco Nardi2, Paolo Vitti1, Claudio Marcocci1, Michele Marinò4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28097622     DOI： 10.1007/s12020-016-1226-9

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  11 in total

1.  A Prospective Investigation of Graves' Disease and Selenium: Thyroid Hormones, Auto-Antibodies and Self-Rated Symptoms.

Authors:  Jan Calissendorff; Emil Mikulski; Erik H Larsen; Marika Möller
Journal:  Eur Thyroid J       Date:  2015-05-27

Review 2.  Diagnosis and management of Graves disease: a global overview.

Authors:  Luigi Bartalena
Journal:  Nat Rev Endocrinol       Date:  2013-10-15       Impact factor: 43.330

3.  Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial.

Authors:  M Leo; L Bartalena; G Rotondo Dottore; E Piantanida; P Premoli; I Ionni; M Di Cera; E Masiello; L Sassi; M L Tanda; F Latrofa; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2016-10-12       Impact factor: 4.256

4.  Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor.

Authors:  Laurent O Mosnier; John H Griffin
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

5.  Role of the underlying thyroid disease on the phenotype of Graves' orbitopathy in a tertiary referral center.

Authors:  Marenza Leo; Francesca Menconi; Roberto Rocchi; Francesco Latrofa; Eleonora Sisti; Maria Antonietta Profilo; Barbara Mazzi; Eleonora Albano; Marco Nardi; Paolo Vitti; Claudio Marcocci; Michele Marinò
Journal:  Thyroid       Date:  2015-02-11       Impact factor: 6.568

Review 6.  Total thyroid ablation in Graves' orbitopathy.

Authors:  F Menconi; M Leo; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2015-03-05       Impact factor: 4.256

7.  An enzyme-release assay for natural cytotoxicity.

Authors:  C Korzeniewski; D M Callewaert
Journal:  J Immunol Methods       Date:  1983-11-25       Impact factor: 2.303

8.  Selenium and the course of mild Graves' orbitopathy.

Authors:  Claudio Marcocci; George J Kahaly; Gerasimos E Krassas; Luigi Bartalena; Mark Prummel; Matthias Stahl; Maria Antonietta Altea; Marco Nardi; Susanne Pitz; Kostas Boboridis; Paolo Sivelli; George von Arx; Maarten P Mourits; Lelio Baldeschi; Walter Bencivelli; Wilmar Wiersinga
Journal:  N Engl J Med       Date:  2011-05-19       Impact factor: 91.245

Review 9.  Prevalence and natural history of Graves' orbitopathy in the XXI century.

Authors:  E Piantanida; M L Tanda; A Lai; L Sassi; L Bartalena
Journal:  J Endocrinol Invest       Date:  2013-04-16       Impact factor: 4.256

Review 10.  Current Insights into the Pathogenesis of Graves' Ophthalmopathy.

Authors:  R S Bahn
Journal:  Horm Metab Res       Date:  2015-09-11       Impact factor: 2.936
View more
  8 in total

1.  Oxidative Stress in Graves Disease and Graves Orbitopathy.

Authors:  Giulia Lanzolla; Claudio Marcocci; Michele Marinò
Journal:  Eur Thyroid J       Date:  2020-11-20

2.  Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves' orbitopathy (GO): a new frontier for GO treatment?

Authors:  G Rotondo Dottore; I Ionni; F Menconi; G Casini; S Sellari-Franceschini; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2017-06-27       Impact factor: 4.256

Review 3.  The risk factors for Graves' ophthalmopathy.

Authors:  Jiamin Cao; Yuhe Su; Zhuokun Chen; Chen Ma; Wei Xiong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-11-17       Impact factor: 3.117

Review 4.  Thinking inside the box: Current insights into targeting orbital tissue remodeling and inflammation in thyroid eye disease.

Authors:  Vardaan Gupta; Christine L Hammond; Elisa Roztocil; Mithra O Gonzalez; Steven E Feldon; Collynn F Woeller
Journal:  Surv Ophthalmol       Date:  2021-09-04       Impact factor: 6.197

Review 5.  A Systematic Review on the Role of Antioxidants in Thyroid Eye Disease.

Authors:  Shadi Akbarian; Samira Chaibakhsh; Mohsen Bahmani Kashkouli; Nasser Karimi; Parya Abdolalizadeh; Hossein Ghahvehchian
Journal:  J Curr Ophthalmol       Date:  2022-04-16

Review 6.  Selenium in the Treatment of Graves' Hyperthyroidism and Eye Disease.

Authors:  Giulia Lanzolla; Michele Marinò; Claudio Marcocci
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-26       Impact factor: 5.555

7.  Therapeutic Effect of Gypenosides on Antioxidant Stress Injury in Orbital Fibroblasts of Graves' Orbitopathy.

Authors:  Chao Ma; Haoyu Li; Wei Liu; Shuwen Lu; Xian Li; Jinyuan Chen; Kaijun Li; Wenzhan Wang
Journal:  J Immunol Res       Date:  2022-09-15       Impact factor: 4.493

Review 8.  The Role of Oxidative Stress and Therapeutic Potential of Antioxidants in Graves' Ophthalmopathy.

Authors:  Tzu-Yu Hou; Shi-Bei Wu; Hui-Chuan Kau; Chieh-Chih Tsai
Journal:  Biomedicines       Date:  2021-12-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.